Glenmark and SaNotize launch FabiSpray in India

13 Feb 2022 , 01:34 AM

Glenmark Pharmaceuticals and Canadian pharmaceutical company SaNOtize Research Development Corp today announced launch of its Nitric Oxide Nasal Spray under the brand name FabiSpray in India; for the treatment of adult patients with COVID-19 who have high risk of progression of the disease Glenmark earlier received manufacturing and marketing approval from the Drugs Controller General of India DCGI for NONS as part of the accelerated approval process FabiSpray Nitric Oxide Nasal Spray is designed to kill the COVID-19 virus in the upper airways It has proven anti-microbial properties with a direct virucidal effect on SARS-CoV-2 NONS when sprayed over nasal mucosa acts as a physical and chemical barrier against the virus preventing it from incubating and spreading to the lungs